Response rates in a key group shrink from 62% to 39% as the company blames a “clerical error”.
ApexOnco Front Page
Recent articles
What similarly acting projects are still unpartnered?
A tumour-agnostic label for Enhertu leads April’s US oncology approvals.
But the group’s attempt to join Janux at the high altar of masking technology falls flat.
A phase 2 head and neck trial missed its primary endpoint, but the group is taking heart from survival data.
The company’s long-delayed pivotal trial is hit by a stronger-than-expected placebo performance.
Hutchmed starts phase 1 with a project in a field where Syndax and Kura have so far been the main players.
The new developer will focus on the crowded KRAS space and PI3Kα/AKT inhibition, which has been hit by toxicity issues.
